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Background: We aim to identify differentially expressed genes (DEGs) and its pathways associated with clinical
activity of relapsing–remitting Multiple Sclerosis (RRMS).
Methods: We screened DEG in blood samples from patients with clinically stable or active RRMS (≥2 relapses or
increase in ≥1 point in the EDSS (due to relapses) in 2 years follow-up), and healthy controls using DNA arrays.
The DEGs identified were validated by RT-PCR in a prospective cohort of MS patients. We used Gene Ontology
(GO) analysis for identifying the associated pathways and Jaspar database for identifying the associated
transcriptions factors.
Results: We identified 45 DEG between the three groups (stable RRMS, active RRMS and control), being 14 of them
significantly different between stable and active RRMS. We validated 14 out of the 45 DEG in the second cohort,
eight out of the 14 being differentially expressed between active and stable patients (ARHGEF7, CASP2, DOCK10,
DSP, ITPR1, KLDHC5, RBBP4, SYTL2). We found an overrepresentation of several pathways associated with
lymphocyte activation. The analysis of regulatory networks identified the gene triplet of Dedicator of Cytokinesis-10
(DOCK10) – Caspase-2 (CASP2) - Synaptotagmin-like 2 (SYTL2) as being co-regulated by common transcription
factors, pointing to lymphocyte activation pathways associated with disease activity.
Conclusions: We describe the triplet DOCK10 - CASP2 - SYTL2 as associated with the clinical activity of RRMS that
suggest the role of lymphocyte activation, type 1 interferon and MAPkinase pathways in driving the presence of
new relapses and disability accumulation.
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Multiple sclerosis (MS) is a clinically heterogeneous
disease with a largely unpredictable course in individual
patients. Clinical management of MS is hampered by the
difficulty in obtaining an accurate prognosis. To achieve
an accurate prognosis during the early or mid-stages of
the disease, and to monitor both disease course and the
response to therapy, it is essential to identify clinical or
biological markers that can serve as surrogate end-points
of the phenotype [1–4]. Such biomarkers would also
greatly facilitate the design and monitoring of clinical
trials to test new disease-modifying drugs by identifying
the most appropriate patient subgroups for a specific ther-
apy of interest.
The activity of relapsing-remitting MS (RRMS) is defined
by the presence of new clinical relapses, presence of new
lesions in the MRI, or increase in disability due to such
relapses. The underlying pathogenesis of RRMS activity is
therefore dependent on the presence of new inflammatory
plaques within the brain parenchyma, as a result of the acti-
vation of the immune system. At present, it is not well
known which pathways are activated during relapses and
which ones are critical for defining a more active disease
activity [5]. Previous gene expression studies have identified
several genes such as GPR3, NFKB, SOCS3, STAT3,
STAT1, CX3CR1, IDO, SLC9A9, HO-1 among others, as-
sociated with a more active disease [6–16]. However, at
present none of such genes have been validated as a known
biomarker of disease activity in MS and also, the pathways
driving a more active disease are not well known [2, 5].
In the present study, we sought to identify gene signature
patterns and pathways associated with RRMS and associ-
ated with clinical activity (relapses and disability worsen-
ing). Although clinical activity was defined prospectively,
our study did not included MRI assessment, limiting the
definition of disease activity and the opportunity to relate
findings with imaging markers. We first screened gene
expression from blood using DNA arrays to identify gene
expression patterns that distinguish between clinically
stable and active disease. Then, we validated these genes by
RT-PCR in an independent prospective cohort of RRMS
patients. Finally, we analyzed the regulatory network of
validated genes, identifying a gene triplet composed by
DOCK10, CASP2 and SYTL2 that pointed to interferon
and T and B cell activation pathways as associated with dis-
ease activity in MS.
Methods
Subjects
We recruited two cohorts of patients with RRMS defined
using the 2005 criteria [17]. Patients were classified as
having clinically stable or active disease using following
definitions: 1) stable disease - no relapses and no changes
in the EDSS score during 2 years of follow-up; 2) activedisease - 2 or more relapses or a 1-point increase in the
EDSS score due to relapses during 2 years of follow-up.
The screening cohort contained RRMS patients in the early
to mid phase of the disease: stable MS patients (n = 3; sex:
1 M/2 F; age: 38 ± 6 years; disease duration: 7 ± 0.8 years;
relapse rate during the 2 years follow-up: 0; EDSS: 0 [range:
0–1]); active MS patients (n = 3; sex: 1 M/2 F; age: 33 ±
7 years; disease duration: 3 ± 0.5 years; relapse rate over the
2 years follow-up: 2.5 ± 0.5, EDSS: 3 [range: 2–4]); and
healthy controls (n = 3; sex: 1 M/2 F; age: 36). None of the
patients in the screening cohort were treated with disease
modifying therapies at the time of the study or in the previ-
ous month. The validation cohort was a longitudinal
prospective cohort of RRMS, including stable MS patients
(n = 20; sex: 5 M/15 F; age: 34.0 ± 5.3 years; disease
duration: 2.6 ± 2.3; relapses follow-up: 0; EDSS: 0.6 ± 0.7),
active MS patients (n = 20; sex: 10 M/10 F; age: 30.5 ± 4.5;
disease duration: 9.7 ± 6.6 years; relapse rate 2 years follow-
up: 2.0 ± 0.5; EDSS: 3.8 ± 1.4) and sex and age matched
healthy controls (n = 20; sex: 8 M/12 F; age: 32.5 ± 9.6 years).
Use of DMTs (Interferon-beta or Glatiramer acetate) were
allowed in the validation cohort, and 33 % of patients were
receiving either therapy. Definition of clinical disease ac-
tivity in this validation cohort was based in longitudinal
prospective data and disability worsening was confirmed
6 months apart.
Ethics, consent and permissions
This study was approved by the Ethics committee of the
Hospital Clinic of Barcelona. Patients were invited to par-
ticipate by their neurologist after signing informed consent.
RNA extraction and DNA arrays
RNA was obtained from whole blood in the screening
cohort using the PAXgeneTM Blood RNA Kit (Quiagen).
For the validation cohort, RNA was obtained from PBMCs
purified using the Ficoll-Paque gradient system (Pharmacia
Biotech). PBMCs were stored in RNAlater stabilization
solution (Applied Biosystems) at − 80 °C until RNA extrac-
tion was performed. RNA was purified using the RNeasy
Mini Kit and digested with the RNase Free DNase Set (both
from Qiagen). The quality and quantity of the RNA was
determined using a NanoDrop 2000 spectrophotometer
and its integrity assessed using a 2100 bioanalyzer (Agilent
Technologies). For DNA array analysis, RNA (6 μg) was
transcribed to cDNA using the SuperScript Choice System
(Life Technologies) according to the Affymetrix Expression
Analysis Technical Manual. Subsequently, cRNA was syn-
thesized using the BioArray HighYield RNA Transcript
Labeling kit (Enzo), purified with the Kit Clean-up module
(Affymetrix) and finally hybridized to the HG-U133 Plus
2.0 DNA array (Affymetrix). For the validation and treat-
ment cohorts, cDNA synthesis was performed from total
RNA using the High-Capacity cDNA Archive Kit
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to the ArrayExpress database (accession code E-GEOD-
2012082010000219) (Additional file 1).
Real time PCR
RT-PCR was performed using Low Density Arrays (LDA:
Applied Biosystems) that were designed selecting TaqMan
assays provided by Applied Biosystems for 45 genes plus
five housekeeping genes using the following criteria: 1)
minimal distance between the Affymetrix probe set and
the Applied Biosystems probe set; 2) no genomic DNA
detection (Additional file 2). All samples were analyzed in
duplicate (384 wells) and the arrays were analyzed inFig. 1 Screening for differentially expressed genes in controls and in patien
expressed between all 3 conditions in patients with stable MS (MS-good), a
identified 4 clusters of genes using as a cut-off a correlation of 0.65; b show
(F-test after FDR correction)triplicate. RT-PCR was carried out in the 7900 Fast Real-
Time PCR system using TaqMan Gene Expression Master
Mix kit (both from Applied Biosystems) as follows: 2 min
at 50 °C; 10 min at 94.5 °C; 40 cycles of 30 s at 97 °C,
1 min at 59.7 °C and 4 °C indefinitely [18]. SDS 2.2.1 soft-
ware was used to analyze migration on microfluid plates.Western blot analysis
Protein levels of DOCK10, CASP2 and SYTL2 were mea-
sured by Western blots from brain tissue as previously
described [6]. Antibodies used for Western blot were as
follows: mouse anti-DOCK10 (Novus Biologicals), mousets with clinically stable or active RRMS. 45 genes differentially
ctive MS (MS-bad) and controls (HC) were found. a Cluster analysis
s the heat map of the 45 DEG grouped in the 4 clusters indentified
Table 1 Differentially expressed genes between clinically stable MS, active MS and controls by DNA array analysis (Additional file 1)
Cluster Gene symbol p-value Description
Cluster #1 TNPO1 2.00E-07 Transportin 1
CXCR3 0.0009282 Chemokine (C-X-C motif) receptor 3
ATP9A 0.0007041 ATPase, Class II, type 9A
CASP2 0.0003848 Caspase 2
PRX 0.0009587 Periaxin
DSP 0.0006427 Desmoplakin
MALAT1 0.0009593 Metastasis associated lung adenocarcinoma
transcript 1; PRO1073
CXorf56 0.0001169 chromosome X open reading frame 56,
hypothetical protein FLJ22965
SSBP4 2.07E-05 single stranded DNA binding protein 4
CCT8 2.13E-05 Chaperonin containing TCP1, subunit 8 (theta)
9.61E-05 Homo sapiens cDNA clone IMAGE:4824925
ELSPBP1 0.0006039 Epididymal sperm binding protein 1
Cluster #2 DOCK10 0.0003135 Dedicator of cytokinesis 10
Cluster #3 ZNF75 0.0005587 Zinc finger protein 75 (D8C6)
MRS2L 0.0007168 MRS2-like, magnesium homeostasis factor
(S. cerevisiae)
TTC10 0.0006527 Tetratricopeptide repeat domain 10, IFT88:
intraflagellar transport 88
0.0002011 Homo sapiens cDNA clone IMAGE:2348094 3
MIA3 0.0004529 Melanoma inhibitory activity family, member 3,
C219-reactive peptide
KMO 7.40E-06 Kynurenine 3-monooxygenase (kynurenine
3-hydroxylase)
FREB 1.19E-05 Fc receptor homolog expressed in B cells; FCRLA
MRPL16 0.0005844 Mitochondrial ribosomal protein L16
RNFT1 0.0004832 ring finger protein, transmembrane 1; PTD016
protein
PRO1693 0.0002505 Homo sapiens PRO1693 protein
ANXA4 0.0002741 Annexin A4
MTM1 0.0004095 Myotubularin 1
KLHDC5 0.0004232 Kelch domain containing 5; KIAA1340 protein
METTL21A 0.0004554 Methyltransferase like 21A
RBBP4 0.0003732 Retinoblastoma binding protein 4
PPP2CB 0.0008942 Protein phosphatase 2, catalytic subunit,
beta isoform
TRAPPC11 0.0003224 Trafficking protein particle complex subunit
11 isoform a
SLC7A7 0.0008726 Solute carrier family 7 (cationic amino acid
transporter, y + system)
ALG13 0.0005845 Asparagine-linked glycosylation 13 homolog;
chromosome X ORF45
PDIA3 0.000489 Protein disulfide isomerase family A; glucose
regulated protein, 58 kDa
INPP4A 0.0007406 Inositol polyphosphate-4-phosphatase, type I,
107 kDa
TFEC 0.0002318 Transcription factor EC
DDX23 0.0006295 DEAD (Asp-Glu-Ala-Asp) box polypeptide 23
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Table 1 Differentially expressed genes between clinically stable MS, active MS and controls by DNA array analysis (Additional file 1)
(Continued)
KIFAP3 0.0003059 Kinesin-associated protein 3
NEK4 0.0002713 NIMA (never in mitosis gene a)-related kinase 4
Cluster #4 ZNF24 0.0009911 Zinc finger protein 24 (KOX 17)
BTBD7 6.14E-05 BTB (POZ) domain containing 7
ITPR1 0.0003003 Inositol 1,4,5-triphosphate receptor, type 1
WDR20 1.07E-05 WD repeat domain 20
LOC100507376 3.00E-07 CDNA FLJ90295 fis, clone NT2RP2000240.
SYTL2 0.0002614 Synaptotagmin-like 2
ARHGEF7 0.0003018 Rho guanine nucleotide exchange factor (GEF) 7
We identified 45 DEGs between stable MS, active MS and healthy controls (F-test, FDR corrected p-value). Cluster analysis grouped the DEG in 4 clusters. Genes
validated in the second cohort are highlighted in bold
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Cruz).
Bioinformatics analysis
In order to estimate the power of our analysis, we assumed
that 95 % of the evaluated probes were not differentially
expressed. We aimed to detect an isolated mean difference
of 1 in log-expression between groups, and set to control
the rate of false positives at 10 %. Assuming a standard
deviation of 0.5 in the difference in log-expression between
groups, the power of our analysis was 0.65. Therefore, it
could be expected that 65 % of genes that showed a two-
fold differential expression between any of the groups
would be identified.
DNA array results were normalized using Micro-
array Suite 5.0 (MAS 5.0; Affymetrix®) and analyzed
using the Biometric Research Branch (BRB) Array Tools
3.2.3 (Dr Richard Simon and Amy Peng Lam). To filter
the genes with the BRB software we used the followingFig. 2 Validation of DEGs in a prospective cohort of patients with stable or
in the validation cohort: ARHGEF7, BTBD7, CASP2, CCT8, DOCK10, DSP, ITPR
normalization factor was calculated using geNorm software and normalized
were performed using the Kruskal-Wallis test with a significance thresholdcriteria: 1) genes with an intensity >10 were assigned a
value of 10; 2) genes were deleted if in the < 20 % of cases
the change gene expression was < 1.5 with respect to the
median, if the percentage of missing values was > 50 %, or
if the percentage of absents was > 70 %. For group
comparison we used the F-test and for pair group com-
parison we used T-test, with a significance threshold set to
p < 0.001. Multiple comparisons were adjusted using the
false discovery method with the significance threshold was
set to p < 0.05. For LDA analysis, we first discarded
samples with an SD > 0.38. The normalization factor
was calculated using geNorm software (https://gen-
orm.cmgg.be) and normalized values were transformed to
a logarithmic scale. For group comparison we used the
Kruskal-Wallis and for pair group comparison we used
Mann–Whitney U non-parametric tests, with a signifi-
cance threshold set to p < 0.01. Multiple comparisons were
performed using the Bonferroni method with the
significance threshold was set to p < 0.05. Statisticalactive disease. Heat map showing the 14 DEGs validated by RT-PCR
1, KLDHC5, PRO1073, RBBP4, SYTL2, TTC10, WDR20, ZNF75. The
values were transformed to a logarithmic scale. Group comparison
set to p < 0.01 after correction for multiple testing (Bonferoni)
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Chicago, USA) and R software (R Core Development
Team, 2011). Correlation between DEG in the array and
RT-PCR study was 0.379. Gene Ontology was analyzed
using Genecodis software (http://www.cnb.csic.es). To
identify transcription factors (TF) that act as common reg-
ulators of the genes of interest, we searched for common
TF binding sites based on frequency matrices obtained
from the Jaspar database [19], using the position specific
weight matrix (PSWM) method with both PSCAN [20]
and R software.
Results
Patients with either clinically active or stable RRMS were
screened, along with healthy sex- and age-matched con-
trols. RNA extracted from whole blood was analyzed
using the HG-U133 Plus 2.0 DNA array (Affymetrix),
obtaining 14,705 of the 54,675 available probes which
fulfilled the criteria for analysis. We performed group
analysis and pairwise comparisons between each of the
three groups. The group analysis identified 45 differen-
tially expressed genes (DEGs) grouped in four clusters
between the three groups (F-test, p < 0.001, FDR correc-
tion) (Fig. 1; Table 1; Additional file 3). Genes GABPA;
FREB; ZNF146; GATA3; KMO; MSH2; GP1BA; DSP;
GIPC2; HAK; SSBP4; SP192; MGC35130; KIAA0826;
C6orf115 significantly discriminate between patients with
clinically stable and active disease (T-test, p < 0.001, FDR
correction). To validate the DEGs associated with clinical
activity in RRMS, we analyzed the expression of the DEGs
by RT-PCR in a second independent cohort of MS pa-
tients. We determined which genes differed significantly
between the three conditions, validating 14 out of theFig. 3 Correlation of DOCK10, SYTL and CASP2 gene expression. The corre
obtained by RT-PCR were performed using the Spearman correlation (R2 =previously identified 45 DEGs that differed significantly
(Kruskal-Wallis test, p < 0.01 after Bonferroni correction
for multiple testing): ARHGEF7, BTBD7, CASP2, CCT8,
DOCK10, DSP, ITPR1, KLDHC5, MALAT-1 (PRO1073),
RBBP4, SYTL2, IFT88 (TTC10), WDR20, ZNF75 (Fig. 2).
Eight out these 14 genes, ARHGEF7, CASP2, DOCK10,
DSP, ITPR1, KLDHC5, RBBP4, SYTL2, were expressed
significantly different between MS patients with clinically
stable or active disease (Mann–Whitney U test, p < 0.01
after Bonferroni correction for multiple testing).
In order to obtain insights about the biological role of
the validated DEGs we performed Gene Ontology (GO)
analysis and regulatory network analysis. The GO analysis
of the DEGs revealed an overrepresentation of several
pathways associated with lymphocyte activation as follows:
a) GO biological process: B cell receptor signaling path-
way, and positive regulation of apoptosis; b) GO molecular
functions: Rho GTPase binding, Rab GTPase binding and
GTPase binding; c) Enrichment analysis of KEGG
pathways: cell adhesion molecules and T cell receptor
signaling. In order to analyze the regulatory networks
associated with the validated DEGs associated with disease
activity, we searched for high correlation in gene expres-
sion as indication or co-regulated expression.
Among the 14 DEGs, we found only one triplet with
high degree of correlation between their expression levels
(by pairwise correlation). The expression of the triplet
DOCK10, CASP2 and SYTL2 was highly correlated
(DOCK10/CASP2: r = 0.799; p = 1.637e-11; DOCK10/
SYTL2: r = 0.591; p = 1.218e-05; and CASP2/SYTL: r =
0.613; p = 4.506e-06; Fig. 3), which would suggest the
existence of master regulators for these gene triplet. The
gene expression levels of the gene triplet DOCK10, CASP2lation of the gene expression levels of DOCK10, SYTL and CASP2
0.65)
Fig. 4 Dock10, SYTL and CASP2 protein levels in PBMCs from MS
patients. Representative Western blots probed to assess the Dock10,
SYTL and CASP2 protein levels in PBMCs from patients and controls
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MS (both clinically stable and active disease) compared to
controls both in the DNA array as well as in the RT-PCR
assays. Also, we analyzed protein levels of the triplet
DOCK10, CASP2 and SYTL2 in PBMCs from MS pa-
tients and healthy controls. We observed higher levels of
Dock10 and Sytl2 protein in MS patients compared with
controls, and we observed a decrease in Caspase-2 in pa-
tients at protein level (Fig. 4). In order to search for com-
mon regulators of the expression of the gene triplet we
performed a TF binding site prediction for DOCK10,
CASP2 and SYTL2 genes. We identified 8 TF as potential
master regulators: MAFB, STAT1, MYF5, FOXQ1, TCF3,
SOX9, SRY and INSM1 (Table 2). A subsequent search of
the Reactome and KEGG databases revealed that the top
two TF MAFB and STAT1 are the downstream TF of the
type I IFN and MAP kinase pathways.
Discussion
We found a gene expression signature associated with
higher clinically disease activity in patients with RRMS. To
identify pathways associated with such increased clinically
disease activity, a bioinformatics search revealed the gene
triplet DOCK10, CASP2 and SYTL2, which are activated in
concert by the MAFB, STAT1 and MYF transcription fac-
tors. This pattern suggests the activation of type I IFN and
MAPkinase pathways in response to immune cell receptor
activation, which is in agreement with previous studies
showing dysregulation of type I interferon pathway in MS
[21, 22]. In addition, GO analysis revealed the involvement
of several pathways related with lymphocyte activation
(Fig. 5).
Several gene expression patterns associated with disease
activity in MS have been identified previously, implicating
T-cell activation and expansion, inflammation and apop-
tosis/cell cycle regulation in disease activity [7–9, 13, 23–
26]. Biological processes that involve DEGs include the
immune response, cell adhesion, cell differentiation, cellular
component movement, signal transduction, blood coagula-
tion, axon guidance, DNA and RNA transcription regula-
tion, and the regulation of cell proliferation. Several of the
TFs identified in the present study have previously been
implicated in MS disease activity by the ANZ consortium
[27], including TCF, MYB and the SOX family. Our find-
ings strongly support the involvement of T and B cell acti-
vation, immune cell signaling, such as type I interferon
signaling, and the regulation of cell proliferation in the
pathogenesis and severity of MS. Further validation of these
biomarkers in multicenter clinical studies will be required
to assess its robustness in different platforms and centers.
The DOCK10/CASP2/SYTL2 gene triplet has been
implicated in lymphocyte activation and function (Fig. 5).
DOCK10 is a member of the dedicator of cytokinesis
family, which acts as activator of the Rho family of small
Table 2 Transcription factors associated with the MS gene
expression pattern
TF Function p
MAFB Transcription factor MafB 0.000198
STAT1 Signal transducer and activator of transcription 1 0.001521
MYF5 Myogenic factor 5 0.005987
TCF3 Transcription factor E2-alpha 0.019014
SOX9 Transcription factor SOX-9 0.024095
SRY Sex-determining region Y protein 0.029105
FOXQ1 Forkhead box protein Q1 0.037121
INSM1 Insulinoma-associated protein 1 0.047677
Identification of the transcription factors (TF) associated with DOCK10, CASP2
and SYTL2 triplet, using the Jaspar database. Results are presented using the
name of the TF in the Jaspar database and the p value of the position-specific
weight matrix analysis, ranked by the p value
Fig. 5 Biological pathways involved in DOCK10 and CASP2 function. Pathw
Reactome databases
Agirrezabal et al. Multiple Sclerosis and Demyelinating Disorders  (2016) 1:7 Page 8 of 10GTPases and mediates signaling by G-protein receptors,
cytokine receptors (protein-kinases), integrins and cad-
herins [28]. Dock10 is mainly expressed in lymphocytes,
and it is activated by the IL-4 and Rho pathways [28],
exhibiting differential splicing between T and B cells [29].
Statins modulate the activity of Rho GTPases, which con-
tributes to the induction of the Th2 phenotype and ame-
liorates disease severity in an animal model of MS [30].
Finally, DOCK10 is also involved in dendrite spine mor-
phogenesis [31]. Taken together with the present results,
these findings implicate DOCK-10 in increased MS dis-
ease activity through its effects on lymphocyte migration
and their differentiation to the Th2 phenotype, and B cell
activation.
Caspase 2 (CASP2) is a protease that is activated in
response to stress (DNA damage) and it appears to
participate more in the regulation of the cell cycle than
in apoptosis [32]. Moreover, CASP2 acts as a tumor
suppressor by inducing cell cycle arrest. CASP2 is highlyays related with both genes were obtained from KEGG and
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ferentiation [33], and is overexpressed in MS patients
during relapses and in response to interferon-beta or
intravenous immunoglobulin therapy [34–36]. In addition,
CASP2 is involved specifically in apoptosis in neuronal
cells [36, 37]. Together with its modulation of the immune
response, this observation strongly suggests that CASP2
contributes to the dampening of lymphocyte proliferation.
We believe differences in CASP2 RNA and protein levels
in our study should be related with functional regulation
of this protein. One hypothesis is that the increase in
protein levels may be due to higher stability or lower
degradation of this protein in immune cells from MS pa-
tients. Such higher levels may suppress the levels of RNA
expression as a negative feedback. Alternatively, regulation
of CASP2 gene expression and efficiency to translation to
protein may differ in MS patients compared to controls,
probably due to pro-inflammatory state, leading to higher
protein levels even with lower RNA synthesis.
Synaptotagmin-like 2 (SYTL2 or SLP2) is a member of a
C2 domain-containing protein family and it is involved in
RAB27A-dependent vesicular trafficking. Among other
functions, SYTL2 participates in the maturation of im-
mune synapses in cytotoxic T cells in order to promote
the exocytoxis of cytotoxic granules containing perforin
[38]. Interestingly, SYTL2 is required for mitochondrial
fusion in response to cellular stress [39], which is critical
for the restoration of mitochondrial function after stress
damage [40]. Its mode of action suggests that SYTL2 par-
ticipates in the stress response during inflammation.
There are several limitations of the present study that
should be noted. The definitions of “active” and “stable” dis-
ease are based on the clinical expression of the disease and
thus, they do not account for sub-clinical activity revealed
by MRI. For this reason, our findings only apply to clinically
active disease and we were not able to correlate our find-
ings with imaging markers of disease activity. Nevertheless,
misclassification of patients due to lack of MRI would in-
crease the number of false negatives more than the number
of false positives, suggesting that validated biomarkers of
the proposed phenotype will persist even in the presence of
the noise generated due to inaccurate clinical descriptions
[3]. Although our datasets were small, we followed a se-
quential analysis in independent cohorts for reducing num-
ber of genes and test performed. Overall, this strategy
decreased the risk of false positives, which is the main limi-
tation in gene expression studies.
Conclusion
In summary, we describe a gene expression pattern com-
posed by DOCK10, CASP2 and SYTL2, which is associated
with a more active course of disease in patients with RRMS.
The biological function of the genes and pathways identi-
fied suggest that clinical disease activity in the early tomedium phase of MS is associated with increased activation
of the adaptive immune system, involving both T and B
cells. Additional studies will be required to further validate
this molecular biomarker as well as for validating such
therapeutic targets for MS and other autoimmune diseases.
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